<abstract><sec><title>Objective</title><p>To evaluate the efficacy, tolerability, and safety of once-daily 1200&#x000a0;mg and 2400&#x000a0;mg SPN-804 (Oxtellar XR&#x02122;, Supernus Pharmaceuticals), an extended-release tablet formulation of oxcarbazepine (OXC), added to 1-3 concomitant antiepileptic drugs (AEDs) in adults with refractory partial-onset seizures, with or without secondary generalization.</p></sec><sec><title>Methods</title><p>The Prospective, Randomized Study of OXC XR in Subjects with Partial Epilepsy Refractory (PROSPER) study was a multinational, randomized, double-blind, parallel-group Phase 3 study. The primary efficacy endpoint was median percent reduction from baseline in monthly (28-day) seizure frequency for the 16-week double-blind treatment period in the intent-to-treat (ITT) population with analyzable seizure data. Other efficacy analyses included proportion of patients with &#x02265; 50% seizure reduction, proportion of patients seizure free, and the relationship between clinical response and plasma concentration.</p></sec><sec><title>Results</title><p>Median percent reduction was -28.7% for placebo, &#x02212;38.2% (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.08 vs placebo) for once-daily SPN-804 1200&#x000a0;mg, and &#x02212;42.9% (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.003) for SPN-804 2400&#x000a0;mg. Responder rates were 28.1%, 36.1% (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.08), and 40.7% (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.02); 16-week seizure-free rates in a pragmatic ITT analysis were 3.3%, 4.9% (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.59), and 11.4% (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.008), respectively. When data were analyzed separately for study site clusters, a <italic>post hoc</italic> analysis demonstrated that both SPN-804 dosages were significantly superior to placebo in median percent seizure reduction (placebo: &#x02212;13.3%; 1200&#x000a0;mg: &#x02212;34.5%, <italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.02; 2400&#x000a0;mg: &#x02212;52.7%, <italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.006) in the North American study site cluster. A concentration&#x02013;response analysis also supported a clinically meaningful effect for 1200&#x000a0;mg. Adverse event types reflected the drug's established profile. Adverse event frequency was consistent with a pharmacokinetic profile in which SPN-804 produces lower peak plasma concentrations vs immediate-release OXC. Once-daily dosing was not associated with any new safety signals.</p></sec><sec><title>Conclusions</title><p>Adjunctive once-daily SPN-804 improved seizure control in patients with inadequately controlled partial-onset seizures. Adverse event occurrence and discontinuations due to adverse events suggest improved tolerability vs previously published data with immediate-release OXC.</p></sec></abstract><sec sec-type="results"><title>Results</title><sec><title>Patient disposition and characteristics</title><p>Of 440 patients screened, 366 patients were randomized to once-daily placebo (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>121), SPN-804 1200&#x000a0;mg (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>122), and SPN-804 2400&#x000a0;mg (<italic>n&#x000a0;</italic>= 123). Analyzable seizure data for the primary efficacy analysis were available for 96.7% (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>117), 89.3% (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>109), and 90.3% (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>111), respectively (Fig.&#x000a0;<xref ref-type="fig" rid="fig01">1</xref>). Of the 111 patients in the 2400-mg group with analyzable seizure data, 26 were patients in whom SPN-804 was down-titrated to 1800&#x000a0;mg/day. Overall, 67.8% of patients completed 16&#x000a0;weeks, with 21.5% of placebo patients discontinuing prematurely compared with 32.8% and 42.3% in the 1200-mg and 2400-mg SPN-804 groups, respectively. The most common reason for study withdrawal was adverse events, accounting for the higher discontinuation rates in the active treatment groups. Based on pill counts, 96.0% (placebo), 93.2% (1200&#x000a0;mg), and 95.1% (2400&#x000a0;mg) of patients were adherent with once-daily dosing.</p><fig id="fig01" position="float"><label>Figure 1</label><caption><p>Study disposition for patients assigned to placebo or Oxtellar XR (SPN-804).</p></caption><graphic xlink:href="ane0129-0143-f1" /></fig><p>Treatment groups were generally well balanced in terms of baseline demographics and disease characteristics (Table&#x000a0;<xref ref-type="table" rid="tbl1">1</xref>). Overall, the mean age was 38.9&#x000a0;years; 55.2% of patients were women. The mean number of years since epilepsy diagnosis was 20.8&#x000a0;years; median monthly seizure frequency at baseline was 6.5 seizures despite ongoing treatment with two or three concomitant AEDs in 67.2% of patients.</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>Demographics and baseline characteristics (safety population)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Characteristics</th><th align="left" rowspan="2" colspan="1">Placebo (<italic>N&#x000a0;=&#x000a0;</italic>121)</th><th align="left" colspan="2" rowspan="1">Oxtellar XR (SPN-804), mg/day</th></tr><tr><th align="left" rowspan="1" colspan="1">1200 (<italic>N&#x000a0;</italic>=<italic>&#x000a0;</italic>122)</th><th align="left" rowspan="1" colspan="1">2400 (<italic>N&#x000a0;</italic>=<italic>&#x000a0;</italic>123)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years), mean&#x000a0;&#x000b1;&#x000a0;SD</td><td align="left" rowspan="1" colspan="1">39.1&#x000a0;&#x000b1;&#x000a0;12.5</td><td align="left" rowspan="1" colspan="1">39.1&#x000a0;&#x000b1;&#x000a0;11.5</td><td align="left" rowspan="1" colspan="1">38.5&#x000a0;&#x000b1;&#x000a0;11.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Female, <italic>n</italic> (%)</td><td align="left" rowspan="1" colspan="1">67 (55.4)</td><td align="left" rowspan="1" colspan="1">71 (58.2)</td><td align="left" rowspan="1" colspan="1">64 (52.0)</td></tr><tr><td align="left" colspan="4" rowspan="1">Race, <italic>n</italic> (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;White</td><td align="left" rowspan="1" colspan="1">107 (88.4)</td><td align="left" rowspan="1" colspan="1">104 (85.2)</td><td align="left" rowspan="1" colspan="1">105 (85.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Black</td><td align="left" rowspan="1" colspan="1">1 (0.8)</td><td align="left" rowspan="1" colspan="1">5 (4.1)</td><td align="left" rowspan="1" colspan="1">1 (0.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Other</td><td align="left" rowspan="1" colspan="1">13 (10.7)</td><td align="left" rowspan="1" colspan="1">13 (10.7)</td><td align="left" rowspan="1" colspan="1">17 (13.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Epilepsy duration (years), mean&#x000a0;&#x000b1;&#x000a0;SD</td><td align="left" rowspan="1" colspan="1">21.2&#x000a0;&#x000b1;&#x000a0;13.9</td><td align="left" rowspan="1" colspan="1">21.3&#x000a0;&#x000b1;&#x000a0;14.5</td><td align="left" rowspan="1" colspan="1">19.8&#x000a0;&#x000b1;&#x000a0;13.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline seizure frequency (seizures/28&#x000a0;days), median</td><td align="left" rowspan="1" colspan="1">7.0</td><td align="left" rowspan="1" colspan="1">6.0</td><td align="left" rowspan="1" colspan="1">6.0</td></tr><tr><td align="left" colspan="4" rowspan="1">Concomitant AEDs, <italic>n</italic> (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;1 AED</td><td align="left" rowspan="1" colspan="1">43 (35.5)</td><td align="left" rowspan="1" colspan="1">36 (29.5)</td><td align="left" rowspan="1" colspan="1">40 (32.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;2 AEDs</td><td align="left" rowspan="1" colspan="1">61 (50.4)</td><td align="left" rowspan="1" colspan="1">68 (55.7)</td><td align="left" rowspan="1" colspan="1">67 (54.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;3 AEDs</td><td align="left" rowspan="1" colspan="1">17 (14.0)</td><td align="left" rowspan="1" colspan="1">18 (14.8)</td><td align="left" rowspan="1" colspan="1">16<xref ref-type="table-fn" rid="tf1-1">*</xref> (13.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Valproate</td><td align="left" rowspan="1" colspan="1">49 (37.2)</td><td align="left" rowspan="1" colspan="1">55 (45.1)</td><td align="left" rowspan="1" colspan="1">62 (50.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Carbamazepine</td><td align="left" rowspan="1" colspan="1">44 (36.4)</td><td align="left" rowspan="1" colspan="1">53 (43.4)</td><td align="left" rowspan="1" colspan="1">49 (39.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lamotrigine</td><td align="left" rowspan="1" colspan="1">37 (30.6)</td><td align="left" rowspan="1" colspan="1">31 (25.4)</td><td align="left" rowspan="1" colspan="1">34 (27.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Levetiracetam</td><td align="left" rowspan="1" colspan="1">27 (22.3)</td><td align="left" rowspan="1" colspan="1">20 (16.4)</td><td align="left" rowspan="1" colspan="1">28 (22.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Topiramate</td><td align="left" rowspan="1" colspan="1">21 (17.3)</td><td align="left" rowspan="1" colspan="1">23 (18.8)</td><td align="left" rowspan="1" colspan="1">23 (18.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Phenytoin</td><td align="left" rowspan="1" colspan="1">4 (3.3)</td><td align="left" rowspan="1" colspan="1">3 (2.5)</td><td align="left" rowspan="1" colspan="1">2 (1.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Other</td><td align="left" rowspan="1" colspan="1">26 (21.5)</td><td align="left" rowspan="1" colspan="1">29 (23.8)</td><td align="left" rowspan="1" colspan="1">18 (14.6)</td></tr></tbody></table><table-wrap-foot><fn><p><italic>N</italic>, total number of patients; <italic>n</italic>, number of patients with analyzable data; SD, standard deviation; AEDs, antiepileptic drugs. </p></fn><fn id="tf1-1"><p>One patient assigned to SPN-804 2400&#x000a0;mg was receiving 4 AEDs.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Efficacy</title><p>The median percent seizure frequency change over the 16-week double-blind treatment period was &#x02212;28.7% with placebo vs &#x02212;38.3% (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.08) for once-daily 1200-mg and &#x02212;42.9% (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.003) in the 2400-mg group (Fig.&#x000a0;<xref ref-type="fig" rid="fig02">2</xref>). The estimated treatment difference favoring SPN-804 over placebo was &#x02212;10.3% (95% CI: &#x02212;22.3, 1.2) for 1200-mg and &#x02212;18.3% (95% CI: &#x02212;30.4, &#x02212;5.8) for 2400-mg group. Secondary endpoints generally mirrored the primary efficacy analysis. Responder rates, that is, proportion of patients with &#x02265;50% seizure frequency reduction (Fig.&#x000a0;<xref ref-type="fig" rid="fig02">2</xref>), were placebo, 28.1%; 1200&#x000a0;mg, 36.1% (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.08); and 40.7% (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.02) of those receiving 2400&#x000a0;mg. The odds ratio comparing the responder rates was 1.67 (95% CI: 0.95, 2.94) for SPN-804 1200&#x000a0;mg vs placebo and 1.98 (95% CI: 1.13, 3.50) when comparing 2400&#x000a0;mg and placebo. For the prespecified pragmatic ITT analysis of seizure freedom, 3.3% of the placebo group, 4.9% (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.53) in the 1200-mg group, and 11.4% (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.008) in the 2400-mg group were seizure free for the entire 16-week blinded treatment period.</p><fig id="fig02" position="float"><label>Figure 2</label><caption><p>Oxtellar XR (SPN-804) vs placebo: Median percent reduction from baseline 28-day seizure frequency (A) and responder rate (B) for the 16-week double-blind treatment period in ITT population with analyzable data. *<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.003; **<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.02 vs placebo. ITT, intent-to-treat.</p></caption><graphic xlink:href="ane0129-0143-f2" /></fig><p>Sensitivity analyses using a completer and a mixed-model repeated-measures analysis did not change the primary statistical outcome that once-daily SPN-804 2400&#x000a0;mg was shown to be significantly superior to placebo, whereas 1200&#x000a0;mg was not. However, in a sensitivity analysis evaluating the potential influence of regional differences in this multinational trial, both SPN-804 dosage groups were significantly superior to placebo in median percent seizure reduction &#x02013; placebo, &#x02212;13.3%; 1200&#x000a0;mg, &#x02212;34.5% (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.02); 2400&#x000a0;mg, &#x02212;52.7% (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.006) among patients (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>106) participating at North American study sites (Fig.&#x000a0;<xref ref-type="fig" rid="fig03">3</xref>). The estimated treatment difference favoring SPN-804 over placebo was &#x02212;26.1% (95% CI: &#x02212;47.9, &#x02212;4.1) for 1200-mg and &#x02212;35.3% (95% CI: &#x02212;59.1, &#x02212;12.5) for 2400-mg group. In contrast, with the substantially higher placebo effect (-33.2%) observed in patients (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>231) from the Eastern Europe/Russia study site cluster (Fig.&#x000a0;<xref ref-type="fig" rid="fig03">3</xref>), neither SPN-804 dosage group was significantly superior to placebo (1200&#x000a0;mg: &#x02212;38.4%, <italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.60; 2400&#x000a0;mg: &#x02212;41.2%, <italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.13) in this subset.</p><fig id="fig03" position="float"><label>Figure 3</label><caption><p>Oxtellar XR (SPN-804) vs placebo: Median percent reduction from baseline 28-day seizure frequency in the North American cluster of study sites (A) and Eastern Europe/Russia cluster (B) in the ITT population. *<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.02; **<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.006 vs placebo. ITT, intent-to-treat.</p></caption><graphic xlink:href="ane0129-0143-f3" /></fig><p>After 16&#x000a0;weeks of double-blind treatment, PGIC score changes were not significantly different for either SPN-804 dosage vs placebo. Mean total QOLIE-31 and subscale scores did not decrease from baseline during SPN-804 or placebo administration in any group. The only significant differences from placebo in QOLIE-31 score changes were significantly smaller increases in the QOLIE-31 subscales of Cognitive Functioning in the 1200-mg and Medication Effects in both SPN-804 groups (<italic>P&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.01 vs placebo).</p></sec><sec><title>Tolerability and safety</title><p>The overall incidence of adverse events (Table&#x000a0;<xref ref-type="table" rid="tbl2">2</xref>) was similar in the placebo (55.4%) and SPN-804 1200-mg groups (56.6%) and was lower than in patients assigned to 2400&#x000a0;mg (69.1%). The incidences of specific adverse events were generally similar for the placebo and SPN-804 1200-mg groups. The most common adverse events were those related to the nervous system, occurring in 31.4% of placebo patients and 38.5% of those receiving 1200&#x000a0;mg, compared with 56.1% in the 2400-mg group. The most frequently reported adverse events &#x02013; dizziness, nausea, somnolence, vomiting, headache, and diplopia &#x02013; were typically dose related. Treatment-limiting adverse event rates were 8.3% and 14.8% in the placebo and 1200-mg groups, respectively; 30.1% in the 2400-mg group discontinued due to adverse events. In the active treatment groups, adverse events resulting in discontinuation occurred primarily during the forced-titration phase (1200&#x000a0;mg: 13/20, 65%; 2400&#x000a0;mg: 26/37, 70%). The fact that 23 patients were down-titrated to 1800&#x000a0;mg also suggests some difficulty with tolerability at 2400&#x000a0;mg.</p><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p>Summary of treatment-emergent adverse events (safety population)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1" /><th align="center" rowspan="2" colspan="1">Placebo (<italic>N&#x000a0;</italic>=<italic>&#x000a0;</italic>121)</th><th align="center" colspan="2" rowspan="1">Oxtellar XR (SPN-804), mg/day</th></tr><tr><th align="center" rowspan="1" colspan="1">1200 (<italic>N&#x000a0;</italic>=<italic>&#x000a0;</italic>122)</th><th align="center" rowspan="1" colspan="1">2400 (<italic>N&#x000a0;</italic>=<italic>&#x000a0;</italic>123)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Any adverse event, <italic>n</italic> (%)</td><td align="left" rowspan="1" colspan="1">67 (55.4)</td><td align="left" rowspan="1" colspan="1">69 (56.6)</td><td align="left" rowspan="1" colspan="1">85 (69.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Serious adverse events, <italic>n</italic> (%)</td><td align="left" rowspan="1" colspan="1">7 (5.8)</td><td align="left" rowspan="1" colspan="1">7 (5.7)</td><td align="left" rowspan="1" colspan="1">10 (8.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Adverse events leading to discontinuation, <italic>n</italic> (%)</td><td align="left" rowspan="1" colspan="1">10 (8.3)</td><td align="left" rowspan="1" colspan="1">18 (14.8)</td><td align="left" rowspan="1" colspan="1">37 (30.1)</td></tr><tr><td align="left" colspan="4" rowspan="1">Incidence, <italic>n</italic> (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Dizziness</td><td align="left" rowspan="1" colspan="1">18 (14.9)</td><td align="left" rowspan="1" colspan="1">24 (19.7)</td><td align="left" rowspan="1" colspan="1">50 (40.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Vomiting</td><td align="left" rowspan="1" colspan="1">11 (9.1)</td><td align="left" rowspan="1" colspan="1">7 (5.7)</td><td align="left" rowspan="1" colspan="1">19 (15.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Headache</td><td align="left" rowspan="1" colspan="1">9 (7.4)</td><td align="left" rowspan="1" colspan="1">10 (8.2)</td><td align="left" rowspan="1" colspan="1">19 (15.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Somnolence</td><td align="left" rowspan="1" colspan="1">11 (9.1)</td><td align="left" rowspan="1" colspan="1">14 (11.5)</td><td align="left" rowspan="1" colspan="1">17 (13.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Diplopia</td><td align="left" rowspan="1" colspan="1">5 (4.1)</td><td align="left" rowspan="1" colspan="1">12 (9.8)</td><td align="left" rowspan="1" colspan="1">16 (13.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Nausea</td><td align="left" rowspan="1" colspan="1">14 (11.6)</td><td align="left" rowspan="1" colspan="1">14 (11.5)</td><td align="left" rowspan="1" colspan="1">15 (12.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Asthenia</td><td align="left" rowspan="1" colspan="1">1 (0.8)</td><td align="left" rowspan="1" colspan="1">4 (3.3)</td><td align="left" rowspan="1" colspan="1">9 (7.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Balance disorder</td><td align="left" rowspan="1" colspan="1">6 (5.0)</td><td align="left" rowspan="1" colspan="1">6 (4.9)</td><td align="left" rowspan="1" colspan="1">8 (6.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Fatigue</td><td align="left" rowspan="1" colspan="1">1 (0.8)</td><td align="left" rowspan="1" colspan="1">7 (5.7)</td><td align="left" rowspan="1" colspan="1">4 (3.3)</td></tr></tbody></table><table-wrap-foot><fn><p><italic>N</italic>, total number of patients; <italic>n</italic>, number of patients. </p></fn></table-wrap-foot></table-wrap><p>Serious adverse events occurred in seven patients each in the placebo (5.8%) and SPN-804 1200-mg (5.7%) groups and in 10 (8.1%) in the 2400-mg group. Of the adverse events classified as serious, none were considered study drug-related in the SPN-804 1200-mg group and three were considered study drug-related in the placebo group (one subject each with erythematous rash, Stevens&#x02013;Johnson syndrome, or dizziness). A fourth patient assigned to the placebo group was the only death in the study (death due to ovarian cancer diagnosed 2&#x000a0;days before randomization). Serious adverse events were considered study drug-related in six patients receiving SPN-804 2400&#x000a0;mg &#x02013; symptomatic hyponatremia (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>1), generalized rash (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>1), dizziness (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>1), vomiting (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>1), and general drug intolerance (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>2), which was characterized by other non-serious adverse events such as dizziness, diplopia, nausea, vomiting, abdominal pain, and/or headache. Study drug was discontinued in all patients with serious adverse events, although SPN-804 was initially down-titrated in one patient before being discontinued due to vertigo/dizziness.</p><p>Only one clinically significant laboratory, vital sign, or ECG abnormality was observed during the study. A shift from normal to lower serum sodium levels was observed in a relatively small subset of patients receiving active treatment (placebo, 1.7%; 1200&#x000a0;mg, 9.8%; 2400&#x000a0;mg, 6.5%). Serum sodium levels were &#x0003c; 130&#x000a0;mEq/l at any point during double-blind treatment in nine patients receiving SPN-804 (1200&#x000a0;mg, <italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>4; 2400&#x000a0;mg, <italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>5) and &#x0003c; 125&#x000a0;mEq/l in two patients (one in each SPN-804 group). One occurrence of a markedly abnormal sodium value resulted in symptomatic hyponatremia and was classified as a serious adverse event.</p></sec><sec><title>Pharmacokinetics and pharmacodynamics</title><p>Based on population PK analysis of plasma MHD concentrations, the mean (SD) C<sub>max</sub> of MHD was 17.9 (5.3) &#x003bc;g/ml in patients receiving once-daily SPN-804 1200-mg and 27.1 (8.7) &#x003bc;g/ml in the 2400-mg group; C<sub>min</sub> concentrations were 12.0 (4.3) &#x003bc;g/ml and 19.4 (7.8) &#x003bc;g/ml, respectively. Clearance was increased 31% in patients receiving carbamazepine, phenytoin, phenobarbital, or valproate as concomitant therapy, but was not increased further when more than one of these agents was given as co-therapy.</p><p>In a concentration&#x02013;response analysis, patients receiving SPN-804 were grouped according to estimated trough (C<sub>min</sub>) MHD concentrations. The breakpoint between subgroups (10&#x000a0;&#x003bc;g/ml) was determined by a sensitivity analysis. The overall median C<sub>min</sub> across SPN-804 groups was 13.9&#x000a0;&#x003bc;g/ml. Median percent seizure frequency reduction was significantly greater in the subgroup with C<sub>min</sub> &#x02265;10&#x000a0;&#x003bc;g/ml MHD (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>125, &#x02212;50%, <italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.02) compared with the &#x0003c;10&#x000a0;&#x003bc;g/ml subgroup (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>41, &#x02212;35.2%) or the placebo group (<italic>n&#x000a0;=&#x000a0;</italic>117<italic>,</italic> &#x02212;28.7%, <italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.0004); the difference in median percent change for &#x0003c;10&#x000a0;&#x003bc;g/ml subgroup vs placebo was not significant (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.57). The C<sub>min</sub> was &#x02265; 10&#x000a0;&#x003bc;g/ml in approximately 85% of patients in the SPN-804 2400-mg group and 66% in the 1200-mg group.</p></sec></sec>